Tectonic secures expedited FDA status for HHT drug as cash stretches to 2029

Tectonic Therapeutic has taken a regulatory step towards a second rare-disease opportunity, with US regulators awarding Fast Track status to TX2100 for hereditary hemorrhagic telangiectasia (HHT) and accepting its application to begin a Phase 1b study. The company disclosed the news on 5 November alongside its third-quarter 2026 results.

The go-ahead for testing in patients builds on an earlier Phase 1a study in healthy volunteers, which, according to the company, produced no serious adverse events. Fast Track is designed to accelerate development and review of treatments for serious conditions with unmet need, and it permits more frequent contact with the agency. The facts provided do not include details of the Phase 1b design, size or timing.

Tectonic's other asset, TX45, is now in patients in a Phase 2a trial called ALPINE, which targets pulmonary hypertension linked to interstitial lung disease (PH-ILD). Separately, the company expects headline results from its Phase 2 APEX trial, in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), by the end of January 2027.

Tectonic reported cash of $234.7 million, which it says will finance operations into the first quarter of 2029. That horizon runs past the APEX readout, meaning the company does not need to raise money to reach that data, on its own estimate. No other financial figures from the quarter were supplied.